Follow-on roundup: Sangamo, Tricida, DBV

Sangamo and Tricida each priced follow-ons soon after their share prices spiked on recent clinical readouts. DBV also raised a follow-on ahead of a planned BLA resubmission.

Sangamo Therapeutics Inc. (NASDAQ:SGMO) raised $126.5 million on Thursday

Read the full 351 word article

User Sign In